Total Funding
89
71
Total FundingSeries A raised
Growth Score
-6 pts
Heat Score
-24 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
13662
Imaginostics is creating the next generation of precision medicine diagnostic and prognostic tools.
Patrick O'Neill: Vice President, Strategic PartnershipsPast Role: Connecticut Innovations, Managing Director, Venture Capital Investments- W Scott Hoge: CTO
About the Company
Imaginostics is a health tech company developing a quantitative vascular MRI platform (ImagiView™) and AI-powered biomarker engine (ImagiSight™) that transforms standard MRI scanners into precision diagnostic instruments — no new hardware required. From a single scan on existing MRI systems, the platform generates individual-patient maps of
microvascular density, blood-brain barrier permeability, and vessel structure. Lead indications include malignant brain neoplasm and Alzheimer's disease. Imaginostics holds FDA Breakthrough Device Designation and a letter of support from Siemens Healthineers, and is backed by the NIH and the Alzheimer's Drug Discovery Foundation.
Women Founded
